Rhesus (Rh) haemolytic disease has been greatly reduced in incidence by the prophylactic programme with anti-D immunoglobulin, but it will not be eliminated. Even with careful documentation and close liaison between medical, nursing and laboratory personnel, there are occasional failures to administer anti-D to Rh-negative women at risk of sensitization following either delivery (Crowle, 1974) or abortion, or after antenatal events which may be associated with transplacental fetomaternal bleeding, eg, amniocentesis, external version or placental abruption; there are also, of course, women who are already D-sensitized but have not yet completed their reproductive careers, while others have antibodies against Rh antigens other than D; very occasionally Rh sensitization may still result from the transfusion of mismatched blood. For these reasons, we will continue to see small numbers of pregnant women with Rh antibodies, but the multidisciplinary teams responsible for their management and for the care of their babies will find it increasingly difficult to maintain practical experience and expertise. There is therefore a clear need to organize care on a regional basis.
In addition to obstetricians and paediatricians with special experience of this problem, multidisciplinary Rh teams must include biochemists, haematologists and blood transfusion specialists, and also radiologists. They must be based on centres with full perinatal facilities, including a neonatal intensive care unit and facilities for both diagnostic ultrasound and intrauterine fetal transfusion.
Such a team was established in 1967 at the Royal
Maternity Hospital, Belfast, where up to that time six consultant obstetricians had shared the responsibility for the supervision of about two-thirds of the Rh-immunized pregnant women in Northern Ireland, which province has a population of some one and three-quarter million persons, and where severe Rh haemolytic disease is a particularly common problem because of a tendency to very high parity even among women who have already had a succession of unsuccessful pregnancies.
Action Line Method
From 1 May 1967, coincident with the adoption of 54 the action line (AL) method of determining the optimal time for intervention-delivery or intrauterine transfusion-in Rh-immunized patients, it was agreed that all such patients should become the responsibility of a single 'Rh clinic' under the author's control. Thenceforth, an increasing number of women were referred to this clinic by their own family doctors and from other hospitals that no longer undertook the management of patients with antibodies: all these patients were classified as 'directly referred'. A small but decreasing number of other hospitals in Northern Ireland retained the majority of their Rh-immunized patients and referred only those in whom the baby was considered to be at very high risk on the basis of the outcome of previous pregnancies: these women were classified as 'transferred patients'.
Because the essential decision in managing pregnancy in Rh-immunized women is to select the optimal time for intervention, based on the presence, severity and likely further trend of haemolysis in the fetus as indicated by the trend of the amniotic fluid bilirubin concentration, our AL method (as originally described by Whitfield et al (1968) , and subsequently extended by Whitfield et al (1970) ) will be outlined.
Amniocenteses, which should be carried out under immediate ultrasonic control to locate both the placenta and a suitable collection of amniotic fluid, are timed in accordance with the previous Rh history. Thus, the first amniocentesis is performed 10 weeks before the time of the earliest previous fetal death due to Rh-incompatibility, or method devised by Liley (1961) to measure the optical density deviation (A OD) at 450 m,t, and this value is plotted on a logarithmic scale against gestation (in weeks). Instead of using prediction zones, such as those devised by Liley, the A OD at 450 m,u and the extrapolation of its trend between serial tests is related to the curved AL (fig 1) to determine when to intervene, the AL having been establishd following restrospective analysis of more than 100 pregnancies.
Up to 33 weeks, the AL indicates the need and time for intrauterine transfusion to avoid imminent fetal death, as in case A with an initial result already beyond the AL, and in cases B and C in which the fetuses were transfused when the extrapolated trends between separate A OD at 450 m,u measurements reached the line. It is not surprising that the AL between 27 and 33 weeks should almost coincide with the demarcation between Liley's top and middle prediction zones and also with the lower limits of the transfusion zones devised by Liggins (1966) and Robertson (1969) . However, it is higher than the critical levels used for transfusion at some other centres (Gordon et al, 1966; Little et al, 1966; Bowman et al, 1969) which in our own cases would have led to some unnecessary fetal transfusions, including several in fetuses which did not even need exchange transfusion following delivery at term.
In case E the initial A OD at 450 m,u value is actually higher than in case C, but a more favourable trend led us to deliver during the 37th week a baby with moderately severe haemolytic disease. It As previously reported (Whitfield, 1970) Liley (1963) .
Following a detailed review of the results in this first three-year period of AL management, it was decided that in future particular attention should be paid to the following five problems: (1) the effect of abnormal amniotic fluid volume on the bilirubin concentration and on the prediction of severity; (2) the occasional unexpected occurrence of acute haemolysis in the fetus; (3) the risk of neonatal respiratory distress and hyaline membrane disease, particularly in babies born very prematurely after intrauterine transfusion; (4) the further development of our standard fetal transfusion techniques; (5) the attempted reduction of extremely high maternal antibody levels by repeated plasmapheresis in early booking patients with histories of multiple previous Rh stillbirth, in an attempt to give some pro ection to the fetus until it provides a big enough target for intrauterine transfusion. In addition it was found administratively efficient to allocate all Rh-negative patients to the Rh clinic, and this policy was also of great value in ensuring that routine repeated antibody screening was always carried out and that anti-D prophylaxis was effective. (Whitfield, 1971) Repeated measurements of antibody protein in more than 400 patients indicated that term delivery without amniocentesis is safe if specific antibody protein remains below 0 5 ,tg per ml. On the other hand, particularly in first affected pregnancies, levels above 4 0 ,Ig per ml suggest that severe haemolytic disease is likely. These findings are in close agreement with those of Fraser and his associates. In addition, the finding by that some improvement in prediction can be obtained by measuring antibody protein as well as bilirubin in the amniotic fluid was confirmed (Lappin, 1973) but it did not seem that this was helpful in determining the optimal time for intervention. group.bmj.com on November 9, 2017 -Published by http://jcp.bmj.com/ Downloaded from ml). In reporting this, Whitfield and Sproule (1974) described five examples of sharply falling lecithin: sphingomyelin ratios apparently associated with acute haemolysis in the fetus, suggesting that severe fetal anaemia may inhibit production and/or release of alveolar surfactant in the fetal lungs. Paradoxically, there were also abnormally high ratios in relation to some other very severely anaemic fetuses, in which it is speculated that there may have been an initial corticosteroid-induced response to stress. Figure 3 illustrates the value of these three ancillary tests. In this patient, a marked rise in serum antibody protein suggested that a fetal haemolytic crisis was imminent; a third amniocentesis showed a sharp reversal in the initially favourable bilirubin trend and, because the virtually static amniotic fluid volume excluded the possibility that this might be due to developing oligohydramnios, intervention was indicated at 33 weeks as a matter of urgency; because the lecithin:sphingomyelin ratio was just satisfactory, the baby was delivered (rather than transfused in utero) then; both the unusually high cord bilirubin level and the extremely rapid development of deep jaundice confirmed the presence of very rapid haemolysis; the severely affected premature infant received two exchange transfusions and survived without respiratory complication.
Intrauterine Fetal Transfusion
The standard techniques used in Belfast for intrauterine fetal transfusion have been reported elsewhere (Whitfield et al, 1972 Regarding the immediate operative mortality of the procedure (table III) , which we define as fetal death within 12 hours of its completion, it is not surprising that this is directly related to technical difficulties in performing the transfusion. We also learned to enter the lower part of the fetal abdomen anteriorly whenever possible, if necessary by altering the fetal position but more often by using a widely angled approach through the maternal flank: it is in such cases that experienced teamwork by the obstetrician and radiologist really counts. Operative mortality varied from a rate of only 7 % when the front of the fetal abdomen was entered to 15 % when the fetal left flank was entered and 24% when the transfusion needle was passed through the right flank and presumably the enlarged fetal liver.
As previously reported (Whitfield et al, 1972) , the estimated percentage of donor red cells from a single intrauterine transfusion persisting in the fetoplacental circulation at birth is greatest when delivery occurs during the second week after transfusion. At this stage in 54 babies we found that at least 80% of the transfused erythrocytes could be accounted for in the circulation, but there was a progressive reduction with a longer transfusion-delivery interval. The same data also confirmed that donor blood is usually very quickly absorbed from the fetal peritoneal cavity, one of our infants having apparently already absorbed 80% of the transfused red cells when it was born 44 hours later. Ascitic fetuses seem to absorb as much or almost as much donor blood as do non-ascitic infants, but liveborn hydropic babies have only very small amounts of donor blood in their circulation.
Intensive Plasmapheresis
Intensive plasmapheresis was first used as a therapeutic measure in Rh-immunized pregnant women in Liverpool (Clarke et al, 1970) , and I am indebted to Dr Lehane of the Liverpool Regional Blood Trans- fusion Service for the following details (Lehane, 1972) . Of 16 Rh-immunized and one Kell-immunized pregnant women treated by repeated plasmapheresis, in only five was this started before 20 weeks and in five it was continued during the last trimester; four women were delivered during the last month of pregnancy after having repeated plasmaphereses but not intrauterine transfusions and two of their babies were Coombs-negative. We were perhaps too reluctant in Belfast to use this approach, other than a a rather desperate attempt to give some protection to the most severely affected Rh-immunized fetuses until they had grown sufficiently to present a feasible target for intrauterine transfusion. Eight of our patients with histories of several Rh stillbirths and with very high antibody levels had repeated plasmapheresis from the end of the first trimester until fetal transfusion became possible at 23 to 24 weeks, about 600 ml of plasma being removed on each of five days in every week. Spontaneous abortion occurred in one patient soon after this programme was started, six fetuses died with hydrops developing while plasmaphereses were still being carried out, and the only surviving infant required three intrauterine transfusions. These disappointing results, and the lack of any real evidence that antibody levels have been reduced, led us to abandon plasmapheresis as a therapeutic measure.
It is unfortunate that no adequate controlled trial of intensive plasmapheresis seems to have been carried out while there were still relatively large numbers of Rh-immunized pregnant women. A very recent report from Bristol and Liverpool describes considerable experience of plasmapheresis in mothers 'diagnosed as carrying babies severely affected with rhesus haemolytic disease', 44 of whom were treated by repeated plasmapheresis and fetal transfusions and a further 52 by plasmaphereses alone (Fraser et al, 1976 ) but it does not provide real evidence that the procedure is of therapeutic value. Not only do the authors of that report not indicate their diagnostic criteria for severe haemolytic disease, either in utero or at birth, or how they define hydrops fetalis, but their claim for the efficacy of intensive plasmapheresis rests largely on a strange belief that 'only 10 % of mothers with a previous history of stillbirths have a successful outcome in the next pregnancy'. In fact, better results following previous stillbirths were reported even before the introduction of amniocentesis and intrauterine transfusion (Walker and potentially strongly sensitizing events is demonstrated in table V. Finally, it must not be forgotten that comprehensive Rh-prophylaxis must also include the informed counselling of parents after any pregnancy in which antibodies were present. Such counselling is based on careful assessment of the perinatal risks in a future pregnancy, according to the previous history in relation to the husband's probable Rhgenotype, and it must of course be supported by an effective contraceptive service.
